SSKN vs DERM vs SKIN vs MCK vs HSIC

For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.

2% revenue growth year-over-year, versus -29. 1% for Journey Medical Corporation (DERM). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 6x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate Journey Medical Corporation (DERM) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Henry Schein, Inc.

(HSIC) is the cheapest at 21. 6x versus McKesson Corporation at 29. 2x. On forward P/E, Henry Schein, Inc. is actually cheaper at 13. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: McKesson Corporation wins at 0. 43x versus Henry Schein, Inc. 's 4. 20x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.

9%, compared to -98. 9% for STRATA Skin Sciences, Inc. (SSKN). Over 10 years, the gap is even starker: MCK returned +339. 0% versus SSKN's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), STRATA Skin Sciences, Inc.

(SSKN) is the lower-risk stock at -0. 38β versus Journey Medical Corporation's 1. 78β — meaning DERM is approximately -566% more volatile than SSKN relative to the S&P 500. On balance sheet safety, Henry Schein, Inc. (HSIC) carries a lower debt/equity ratio of 77% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.

2% versus -29. 1% for Journey Medical Corporation (DERM). On earnings-per-share growth, the picture is similar: The Beauty Health Company grew EPS 55. 6% year-over-year, compared to -242. 9% for Journey Medical Corporation. Over a 3-year CAGR, MCK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Henry Schein, Inc.

(HSIC) is the more profitable company, earning 3. 0% net margin versus -30. 1% for STRATA Skin Sciences, Inc. — meaning it keeps 3. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HSIC leads at 5. 7% versus -27. 6% for SSKN. At the gross margin level — before operating expenses — SKIN leads at 65. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, McKesson Corporation (MCK) is the more undervalued stock at a PEG of 0. 43x versus Henry Schein, Inc. 's 4. 20x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Henry Schein, Inc. (HSIC) trades at 13. 2x forward P/E versus 69. 9x for Journey Medical Corporation — 56. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DERM: 135. 0% to $11. 75.

In this comparison, MCK (0.

4% yield) pays a dividend. SSKN, DERM, SKIN, HSIC do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, STRATA Skin Sciences, Inc.

(SSKN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 38)). Journey Medical Corporation (DERM) carries a higher beta of 1. 78 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SSKN: -99. 6%, DERM: -46. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SSKN (Healthcare) and DERM (Healthcare) and SKIN (Consumer Defensive) and MCK (Healthcare) and HSIC (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SSKN is a small-cap quality compounder stock; DERM is a small-cap quality compounder stock; SKIN is a small-cap quality compounder stock; MCK is a mid-cap high-growth stock; HSIC is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.